News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
Taconic Biosciences' Board of Directors selected Nancy to succeed Dr. Robert Rosenthal as chief executive officer (CEO).
"Dr. Bob Rosenthal and I along with the previous Taconic board of directors developed a 2-year succession plan to prepare me to lead Taconic, allowing Dr. Rosenthal to focus on inorganic growth initiatives and partnerships," Sandy told us.
"Taconic will continue delivering high value models and services, helping researchers spend their valuable time on drug development rather than generating advanced models and breeding them," she added.
"Geographically, we expanding our global footprint by developing partnerships in China and on the west coast, where we already have a significant customer base. Additionally, we will fully leverage our new relationship with the University of North Carolina at Chapel Hill to add exciting new models to our product line and develop a suite of services for microbiome research."
Rosenthal was CEO for four and a half years and will continue to lead external growth initiatives as chief innovation officer. He also holds positions on the Taconic Scientific Advisory Board and Board of Directors.
Effective January 14, Sandy now holds the company’s top leadership position after joining Taconic in January 2016.
Prior to Taconic, Sandy worked at several companies including Perkin Elmer, Magellan Biosciences, and Cardiac Science.